A unified approach for subgroup identification and individualized treatment recommendation with applications to randomized control trials and observational studies

[1]  Eric B. Laber,et al.  A Robust Method for Estimating Optimal Treatment Regimes , 2012, Biometrics.

[2]  J. Robins,et al.  Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers , 1992 .

[3]  D. Horvitz,et al.  A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .

[4]  Sara T Brookes,et al.  Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. , 2004, Journal of clinical epidemiology.

[5]  D. Zeng,et al.  Recent development on statistical methods for personalized medicine discovery , 2013, Frontiers of Medicine.

[6]  Michael R. Kosorok,et al.  Robust Hybrid Learning for Estimating Personalized Dynamic Treatment Regimens , 2016, 1611.02314.

[7]  L. Tian,et al.  Analysis of randomized comparative clinical trial data for personalized treatment selections. , 2011, Biostatistics.

[8]  Craig D. Shriver,et al.  Breast Cancer in the Personal Genomics Era , 2010, Current genomics.

[9]  Lei Chen,et al.  The mean does not mean as much anymore: finding sub-groups for tailored therapeutics , 2010, Clinical trials.

[10]  J. M. Taylor,et al.  Subgroup identification from randomized clinical trial data , 2011, Statistics in medicine.

[11]  S. Lagakos.  The challenge of subgroup analyses--reporting without distorting. , 2006, The New England journal of medicine.

[12]  I. Lipkovich,et al.  Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulations , 2011, Statistics in medicine.

[13]  Xiaogang Su,et al.  Subgroup Analysis via Recursive Partitioning , 2009 .

[14]  M. Hanefeld,et al.  A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[15]  M. Cronin,et al.  Pharmacogenomics: The promise of personalized medicine , 2000, AAPS PharmSci.

[16]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[17]  P. Rothwell.  Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.

[18]  Susan A. Murphy,et al.  A Generalization Error for Q-Learning , 2005, J. Mach. Learn. Res..

[19]  Ilya Lipkovich,et al.  Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder , 2013, International journal of methods in psychiatric research.

[20]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[21]  Dirk Eddelbuettel,et al.  Rcpp: Seamless R and C++ Integration , 2011 .

[22]  Donglin Zeng,et al.  Estimating Individualized Treatment Rules Using Outcome Weighted Learning , 2012, Journal of the American Statistical Association.

[23]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[24]  Lu Tian,et al.  Effectively Selecting a Target Population for a Future Comparative Study , 2013, Journal of the American Statistical Association.

[25]  S. Murphy,et al.  PERFORMANCE GUARANTEES FOR INDIVIDUALIZED TREATMENT RULES. , 2011, Annals of statistics.

[26]  S. Hunt,et al.  Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.